jobs

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

818.93 -10.81 (-1.30%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Could This Near Trillion-Dollar Stock Be a Millionaire Maker?
Size means little in light of this company's prospects. 
Via The Motley Fool
Market Volatility Soars Ahead Of Elections, Tech Earnings Mixed, Strikes And Hurricanes Knock Employment Down: This Week In The Markets
The U.S. stock market experienced a setback at the end of October, breaking a five-month winning streak. Are politics to blame? 
Via Benzinga
Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH
Madrigal sells an approved MASH treatment that blasted third-quarter sales views out of the water. 
Via Investor's Business Daily
Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
Novo Nordisk's ESSENCE trial of semaglutide 2.4 mg shows significant improvements in liver fibrosis and steatohepatitis outcomes, with regulatory filings planned for 2025. 
Via Benzinga
Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip
The market overreacted to Lilly's Q3 earnings miss and full-year guidance cut. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Eli Lilly Stock Is Sinking Today
The big pharmaceutical company provided a disappointing Q3 update. 
Via The Motley Fool
Is Eli Lilly Stock a Buy?
Eli Lilly has been a huge winner with its GLP-1 drugs. 
Via The Motley Fool
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
The major indexes declined, but haven't fallen apart. 
Via Investor's Business Daily
Viking Therapeutics Stock: A Pre-Election Bet Worth Considering
Viking Therapeutics is making headway in the weight loss drug market; but even though the payoff is years away, there's still plenty of upside for investors 
Via MarketBeat
Nasdaq Tumbles Over 100 Points Ahead Of Big Tech Earnings: Fear & Greed Index Remains In 'Greed' Zone
Via Benzinga
A Closer Look at Eli Lilly's Options Market Dynamics
Via Benzinga
Are Eli Lilly's Lowered Expectations a Reason to Sell?
Accounting for an acquisition Eli Lilly completed in August made a big impact on earnings expectations for 2024. 
Via The Motley Fool
Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO
The company expects to have topline results from a Phase 2 study later this year. 
Via Investor's Business Daily
AMD Earnings Show Power Of Nvidia Software, ADP Data Defies Expectations
To gain an edge, this is what you need to know today. 
Via Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio. 
Via Benzinga
Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast
Via Benzinga
Exposures Fossil Fuels
Eli Lilly (LLY) Q3 2024 Earnings Call Transcript
LLY earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Wall Street Mixed, Semiconductors Tumble As AMD Disappoints, Alphabet Rallies, SMCI Plummets: What's Driving Markets Wednesday?
Wall Street experienced a mixed trading session on Wednesday as investors weigh a batch of corporate earnings and fresh economic data. 
Via Benzinga
Eli Lilly CEO David Ricks On Q3 Results: The Underlying Growth Story Is Fantastic
Eli Lilly reported its latest quarterly earnings. 
Via Talk Markets
O-I Glass Posts Downbeat Results, Joins AMD, Qorvo And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
Eli Lilly Q3 Earnings: Mounjaro Sales More Than Double, Takes $2.98 Billion Hit To Profit, Cuts Annual Outlook, Stock Tanks
Eli Lilly's stock falls as Q3 earnings miss estimates. 2024 guidance lowered due to IPR&D costs. 
Via Benzinga
Topics Earnings
Exposures Financial
Eli Lilly Dives On Earnings Miss As Diabetes, Weight-Loss Drugs Fall Short
The pharma giant blamed "inventory decreases in the wholesaler channel." 
Via Investor's Business Daily
Topics Earnings
Exposures Financial
Zepbound, Mounjaro Maker Eli Lilly Climbs In Wednesday Pre-Market As Impressive 51% YTD Gain Sparks Stock Split Speculation
Its products Mounjaro and Zepbound generating over $4 billion in the last quarter. 
Via Benzinga
A Once-in-a-Decade Investment Opportunity: 1 Pharmaceutical Stock to Buy Now Hand Over Fist and Hold for Years
Eli Lilly has a number of lucrative opportunities that should serve as tailwinds for sustained growth. 
Via The Motley Fool
Eli Lilly Says New Data Can Potentially Provide Path To Improved Donanemab Profile By Lower Risk Of Imaging Abnormalities In Patients With Early Alzheimer's
Eli Lilly's Phase 3b study reveals a 41% reduction in amyloid-related imaging abnormalities in Alzheimer's patients using a modified titration of donanemab. 
Via Benzinga
Eli Lilly Q3 Earnings On Deck: Stock Split Rumors Heat Up With Weight Loss Gains
Eli Lilly reports Q3 earnings on Wednesday. Stock up 58% in past year, potential to split to attract investors in growing weight loss market. 
Via Benzinga
Will New CFO Offer Annual Guidance For Google Stock?
When Alphabet reports Q3 earnings, Wall Street analysts will look for its new CFO Anat Ashkenazi to set her priorities. 
Via Investor's Business Daily
1 Huge New Reason to Buy Eli Lilly or Novo Nordisk Stock Right Now and Hold It Forever
One key disease-prevention market is drawing closer to being within reach. 
Via The Motley Fool
Eli Lilly's Latest Setback Could Portend an Unexpected Headwind for the Stock
The odds of its new drug getting established in the U.K. are now much lower. 
Via The Motley Fool
Neuralink's Promise For Alzheimer's Has A Crucial Time Window — Elon Musk Explains Why
Elon Musk hinted that Neuralink may develop a brain implant to treat early-stage Alzheimer's, although he noted its limited effectiveness for advanced cases due to extensive neuronal loss. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News Instagram Instagram
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

922 Allowance Ave SE
Medicine Hat, AB T1A 3G7

Office hours: 8:30 a.m.-4:30 p.m. Monday to Friday, closed Saturday Sunday and statutory holidays.

[P] 403.527.1101
[F] 403-527-0737

Print Advertising: 403.528.5659
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2024 The Medicine Hat News